Duke-NUS Medical
School's Groundbreaking Stem Cell Therapy Offers Hope for Heart Failure
Patients
In a groundbreaking development, Duke-NUS
Medical School has made significant strides in the field of heart failure
treatment by harnessing the power of stem cells.
Their innovative stem cell
therapy shows immense promise in repairing damaged heart tissue and improving
heart function when transplanted into the affected area.
This breakthrough procedure has the potential
to transform the lives of patients suffering from heart failure, mitigating the
risk of complications such as arrhythmias or tumors, while fostering the
regeneration of healthy cardiac tissue.
Heart failure remains a leading cause of
mortality worldwide, primarily caused by ischaemic heart disease, which occurs
when the heart's blood flow is obstructed, leading to the death of heart muscle
cells—commonly known as a heart attack.
However, Duke-NUS researchers have developed a
unique protocol that involves cultivating pluripotent stem cells in the
laboratory, allowing them to grow into heart muscle precursor cells. These
precursor cells have the ability to develop into various types of heart cells,
facilitating the regeneration of damaged tissue.
In preclinical trials, the team injected these
precursor cells into the damaged region of the heart affected by myocardial
infarction. Remarkably, the cells successfully grew into new heart muscle
cells, effectively restoring the damaged tissue and significantly improving
heart function.
Dr. Lynn Yap, an assistant professor at Lee
Kong Chian School of Medicine, Nanyang Technological University, Singapore, and
the study's first author, expressed excitement about the rapid engraftment of
the transplanted stem cells and the subsequent growth of new heart tissue,
suggesting that this protocol has the potential to become a safe and effective
cell therapy option.
Importantly, the Duke-NUS procedure
circumvents potential risks associated with other approaches. Unlike previous
studies where the transplantation of already beating heart muscle cells
resulted in fatal side effects such as ventricular arrhythmia, the Duke-NUS
researchers transplanted non-beating heart cells into the damaged area.
These cells then expanded and synchronized
their rhythm with the rest of the heart, significantly reducing the incidence
of arrhythmia by half. Additionally, concerns about tumor formation, a common
issue with stem cell therapies, were alleviated as the transplanted cells did
not trigger tumor growth.
The impact of this technology extends beyond
heart failure treatment. Professor Karl Tryggvason, from Duke-NUS'
Cardiovascular & Metabolic Disorders (CVMD) Programme and the senior author
of the study, is leading other studies to adapt this regenerative medicine
method for patients with diabetes, macular degeneration in the eyes, and those
requiring skin grafts.
By utilizing laminins, specific proteins
crucial for cell interactions with their surrounding structures, the team has
developed a reproducible method to generate the right cells for
transplantation.
The potential of this groundbreaking therapy
has garnered attention worldwide, leading to its licensing to a Swedish biotech
startup earlier this year. With continued research and development, this stem
cell therapy could revolutionize the field of regenerative cardiology and offer
renewed hope to countless individuals living with heart failure.
No comments :